Catheter Precision reports Q2 revenue of $94,840; approves 1-for-10 reverse stock split

Catheter Precision, Inc.

Preliminary Q2 2024 revenue $94,840, including first LockeT sales ($40,500) and VIVO ($54,340).
Six-month 2024 revenue $176,923; 15% sequential quarter-over-quarter growth.
Board approved 1-for-10 reverse stock split effective July 15, 2024; shares reduce from 8.4M to ~839K.
Series A Preferred conversion issued 814,228 common shares on July 1, 2024.
New CCO Marie Claude Jaques hired in May; sales pipeline growing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.